[6] O'Donnell J.A., Gelone S.P.,
Fluoroquinolones,
Infect. Dis. Clin. North Am.
, 14(2): 489–513 (2000).
[9] Wentland M.P., Lesher G.Y., Reuman M., Gruett M.D., Singh B., Aldous S.C., Dorff P.H., Rake J.B., Coughlin S.A.,
Mammalian Topoisomerase II Inhibitory Activity of 1-cyclopropyl-6, 8-difluoro-1, 4-dihydro-7-(2, 6-dimethyl-4-pyridinyl)-4-oxo-3-Quinolinecarboxylic Acid and Related Derivatives,
J. Med. Chem., 36(19): 2801–2809 (1993).
[12] Karlowsky J.A., Adam H.J., Desjardins M., Lagacé-Wiens P.R., Hoban D.J., Zhanel G.G., Baxter M.R., Nichol K.A., Walkty A., Canadian Antimicrobial Resistance Alliance (CARA, 2013.
Changes in Fluoroquinolone Resistance over 5 Years (CANWARD 2007–11) in Bacterial Pathogens Isolated in Canadian Hospitals,
J. Antimicrob. Chemother., 68: i39–i46 (2013).
[24] Petersen U., Schrock W., Habich D., Krebs A., Schenke T., Philipps T., Grohe K., Endermann R., Bremm K.D., Metzger K.G.,
Quinolonecarboxylic Acids,
U.S. Patent: 5480879 (1996
).
[28] “Global and Alliance for TB Drug Development Handbook of Anti-Tuberculosis Agents”, "
Moxifloxacin".
Tuberculosis,
88(2): 127–131(2008).
[43] Mohammadi Ziarani, G., Badiei, A., Azizi, M., Zarabadi, P.,
Synthesis of 3, 4-dihydropyrano [c] Chromene Derivatives Using Sulfonic Aacid Functionalized Silica (SiO2PrSO3H),
Iran. J. Chem. Chem. Eng. (IJCCE), 30(2): 59–65 (2011).